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Abstract
Background:  Diabetes is common in the older population and is increasing. Glycated hemoglobin
(HbA1c) is an indicator of average blood glucose concentration over the past three months. The HbA1c
test is currently one of clinical methods used to check diabetes control. Recent studies have suggested
diabetes is a risk factor for dementia, cognitive dysfunction and physical disability. In addition, there have
reported the relationship between HbA1c and mortality on all cause, cardiovascular disease and cognitive
function, but few studies have investigated the relationship concentrating on the older population.
The aim of this study is to investigate the association between the level of HbA1c and mortality from all
causes, incident cardiovascular disease, cognitive decline and physical disability in people aged 65 and over
in England and Wales.
Methods: 1139 men and women aged 69 years and over who were participants in a ten year population
based ageing multi-centre, longitudinal study who had HbA1c measurements after 5–6 years of follow up.
All participants were flagged for death notification including causes at the Office of National Statistics.
Information on health including vascular conditions, cognitive status, physical function and dementia were
available from the study both before and after the HbA1c measurement. Survival analyses and logistic
regression were conducted.
Results: Mortality from all causes, cardiovascular and ischaemic heart disease increased with increasing
HbA1c. Participants with diagnosed diabetes or who had HbA1c≥ 7% but no self-reported diabetes had
increased mortality risk from all causes and cardiovascular diseases. The respondents in the group HbA1c
≥7% who had not been diagnosed with diabetes had a significantly higher risk (odds ratio = 4.8 95% CI: 1.1
to 21.6) of developing dementia. Individuals who had self-reported diabetes but a HbA1c level <7% had
mortality and dementia incidence comparable to individuals without diabetes and HbA1c <7%.
Conclusion:  The findings support previous reports that bio-markers of glucose metabolism are
associated with long term outcomes, such as mortality and dementia.
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Background
Diabetes is already common in the older population and
is increasing. In the year 2000, 12% of people aged 65 to
70 years and 15% of people over age 80 have been esti-
mated to have diabetes globally [1]. It is established that
diabetes is an independent risk factor for eye, kidney and
neurological disease as well as for cardiovascular morbid-
ity and mortality [2]. Two systematic reviews have con-
firmed its importance as a risk factor for dementia [3,4].
Recent evidence suggests that diabetes is also a risk factor
for cognitive dysfunction [3,4] and physical disability [5].
Glucose sticks to the haemoglobin to make a 'glycosylated
haemoglobin' molecule, called haemoglobin A1C or
HbA1c in red blood cells. The more glucose in the blood,
the more HbA1c will be present in the blood. As red cells
live for 8–12 weeks before they are replaced, HbA1c level
is an indicator of average blood glucose concentration
over the past three months rather than blood glucose
which fluctuates. The HbA1c test is currently one of the
clinical methods used to check diabetes control. Clinical
practice recommendations suggest a HbA1c goal of <7 %
[6]. In general, the higher the HbA1c value, the higher the
risk of having diabetes and of developing complications
from diabetes.
Recently the EPIC-Norfolk study, a large epidemiological
study, reported a continuous relationship between HbA1c
and mortality on all cause, cardiovascular, ischaemic heart
disease in men and women aged 45 – 79 years old even
within the "normal range" of values [7,8]. Shankar and
colleagues have also reported that elevated glycosylated
haemoglobin levels were associated with all-cause and
cardiovascular mortality in type 1 diabetes [9]. There have
been inconsistent reports on HbA1c levels in relation to
cognition. Worrall and colleagues have reported a non sig-
nificant trend for individuals with extreme lower or higher
HbA1c levels to have poorer cognitive function as assessed
by the Modified Mini-Mental State but not the Delayed
Word Recall Test [10]. Two further studies showed no
relationship between diabetes and cognition [11,12].
Few studies have investigated the relationship concentrat-
ing on the older population. An increasing risk of cogni-
tive decline with age especially among older people is well
established, but whether HbA1c levels are related to cogni-
tive function and these changes in the older population is
not yet clear. Impairment in physical ability is common in
old age. Diabetes is a risk factor for impairment of normal
physical activity [13], and in one population based study
deficits in activities of daily living were reported by 53%
of people with diabetes aged 70 years and over [5]. It is
uncertain if the relation between HbA1c level and condi-
tions associated with diabetes such as vascular disease,
cognitive impairment and physical disability shows a
threshold effect or whether there is a dose response rela-
tionship. This paper investigates the relationship between
HbA1c levels and mortality, cognitive function and physi-
cal disability in the older population in England and
Wales.
Methods
Study population
The Medical Research Council Cognitive Function and
Ageing study (CFAS) is a multi-centre, longitudinal study
of people aged 65 years and over (over 18,000 individuals
at baseline). It is predominantly a two-phase population
based interview study, with annual or biennial follow-
ups. There are six CFAS centres, two in rural areas (Cam-
bridgeshire and Gwynedd, Wales) and four in urban areas
(Nottingham, Newcastle, Oxford and Liverpool). Details
of the CFAS study design have been published previously
[14,15] (see Figure 1 for a simplified flow diagram).
Interviews
Blood was collected at the third wave of interview in 1996
– 1998, between four to six years after the start of the study
in all centres except Oxford. All those who had previously
received an assessment interview including the study diag-
nosis were invited to participate in this wave of the study.
Sampling at prevalence assessment was weighted towards
cognitive impairment. Blood samples were requested
from all respondents, and samples were collected from
69% (1,150 out of 1654). An EDTA-anticoagulated blood
sample was sent by post to Cambridge, and assayed at the
Department of Clinical Biochemistry, University of Cam-
bridge. The HbA1c assays were carried out using high-per-
formance liquid chromatography (HPLC) on a Bio-Rad
Diamat Automated Glycosylated Haemoglobin Analyser
(Hemel Hempstead, United Kingdom) that was DCCT-
aligned. The HbA1c readings were fed back to the GPs. 11
samples were undated, and were excluded. The HbA1c
measurements from 1,139 respondents were used in the
analysis. A cut-off point of 7% has been used during this
investigation for diagnosis of diabetes, as it has been
reported to provide produced the maximum sum of sensi-
tivity and specificity [16] and has been used in similar
studies such as EPIC-Norfolk study [8]. The respondents
were divided into five categories: those with self reported
diabetes, those with a HbA1c level ≥7% but who did not
report they had been previously diagnosed with diabetes,
as we believe that some of the people who were diagnosed
with diabetes have been treated and monitored, therefore
there will be some different impacts on cognitive function
and physical function between these two groups. Three
further groups defined by classifying the remaining
respondents as low, medium and high tertiles of HbA1c,
the ranges for the three groups are 3.7%–5.2%, 5.3%–
5.7% and 5.8%–6.9%,BMC Public Health 2008, 8:54 http://www.biomedcentral.com/1471-2458/8/54
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MRC CFAS, flow diagram of study Figure 1
MRC CFAS, flow diagram of study.BMC Public Health 2008, 8:54 http://www.biomedcentral.com/1471-2458/8/54
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Two years after the blood collection interview, a subgroup
of respondents was interviewed again, and after another
two years, all surviving respondents (excluding Liverpool)
were interviewed (year 10 interview). 524 out of the 1139
respondents with a HbA1c measurement had at least one
follow up interview. The median follow-up time from
blood collection was 5 years.
Exposure/risk measurement
Information on residence, marital status, main occupa-
tion, social and service contacts, physical health and well-
being was collected at baseline interview. Change in any
of these variables was obtained from follow-up inter-
views. Data on health conditions including detailed cog-
nitive function and physical function are available both
before and after the HbA1c measurement in those individ-
ual with follow up interviews.
Risk factors for cognitive impairment measured by self
report or informant at baseline interview included history
of diabetes, heart attack, stroke and hypertension. The
participants with self reported diabetes were defined as
those answered "Yes" to the question: "Have you ever had
sugar diabetes?" in any interviews. Smoking status was
classified into three categories: non-smoker (never
smoked), ex-smoker (stopped at least 5 years ago) and
current smoker.
Definition outcomes
All participants were flagged for death notification at the
Office of National Statistics (ONS). There had been 619
deaths in the HbA1crespondents by the end of 2004 (ver-
sion 8.0 of data). Cause of death was established from
death certificates. Cardiovascular death was defined as
International Classification of Disease Revision 9 (ICD9)
codes 400–438, ischaemic heart disease death as ICD 9
codes 410–414 and cerebro-vascular disease death as ICD
9 codes 430–438 anywhere on the death certificate.
Cognitive function was measured using the Mini Mental
State Examination (MMSE) score [17], which tests a range
of cognitive abilities and provides a total score from 0 to
30, and dementia of diagnosis using the computerized
algorithm AGECAT organicity level of the Geriatric Mental
State Examination (GMS Automated Geriatric Examina-
tion for Computer Assisted Taxonomy) [18].
Respondents have been classified as demented, not
demented and missing diagnosis using the criteria:
• Demented: AGECAT level O3 and above
• Not demented: AGECAT O0, O1, or O2
• Missing: AGECAT level missing
Individuals unable to complete the full interview were
diagnosed using vignette, informant information and
interviewer observations.
An incident dementia case was defined as a respondent
becoming demented after the interview at which blood
was collected.
The activities of daily living (ADL) impairment has been
defined using the hierarchy of IADL (instrumental activi-
ties of daily living) and/or ADL [19] and based upon the
concept of interval of need [20]. Participants' mobility
was also rated by the interviewer, as usually ambulant
non-housebound, usually ambulant housebound, chair-
fast permanently, and bedfast permanently. An incident
ADL impaired case was defined as a respondent becoming
impaired after the interview when blood was collected.
Due to differences in study design and data collected,
individuals in Liverpool (n = 168) only contributed to the
analysis of mortality.
Statistical methods
Descriptive analysis was carried out to explore the charac-
teristics of the population, the distribution of variables
and the relationship between HbA1c and vascular diseases
risk factors. Analysis of variance (ANOVA) was used to
investigate differences on HbA1c levels between categories
of demographic variables and risk factors. Linear regres-
sion was used to investigate trends in continuous and
ordinal variables.
Survival analysis was used to investigate the association
between HbA1c level and mortality from all causes, cardi-
ovascular disease, cerebral disease, ischaemic heart dis-
ease and other causes. Cox proportional hazards models
were used to determine the contribution of risk factors to
mortality. Logistic regression models have been used to
examine of relationships between HbA1c level and inci-
dence of dementia, and incidence of physical disability.
Proportional hazards assumptions were tested using Kap-
lan-Meier curves. The analysis uses inverse probability
weighting to adjust for the study design using methods
described previously [21]. Analysis was performed with
STATA version 8.
Ethical approval
All CFAS interviewing and blood collection have been
covered under local and multi-centre ethical approval.
All research has been undertaken independently of the
funding bodies.BMC Public Health 2008, 8:54 http://www.biomedcentral.com/1471-2458/8/54
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Results
Characteristics
HbA1c levels ranged from 3.7% to 13.9% with a skewed
distribution with median 5.6%, and mean 5.8%. 91% of
values were below 7%, and no differences were found
between centres (p = 0.83).
Table 1 shows the characteristics of 1,139 respondents cat-
egorised by HbA1c level and self reported diabetes. Men
without previously diagnosed diabetes were more likely
to have a HbA1c level ≥7%. Respondents in HbA1c level
≥7% category were older and had lower MMSE scores.
Those respondents who were in either self reported diabe-
tes or HbA1c level ≥7% categories were more likely to have
IADL and/or ADL impairment. Respondents with diag-
nosed diabetes were more likely to report having had a
heart attack or stroke.
The mean value of HbA1c for smokers and those who
reported high blood pressure was systematically higher in
the 1,004 respondents whose HbA1c was under 7%. Oth-
erwise there were no systematic or significant differences
between the groups with 'normal' HbA1c levels.
Mortality
By the end of 2004, 54% of the 1139 respondents had
died. The number of deaths was similar in each the first
five follow up years, and increased sharply thereafter. The
median follow up time was 3 years from blood collection
and interquartile range was 1.4 to 5.0 years for those who
had died.
Figure 2 displays the cumulative mortality curves from all
cause deaths by five categories of respondents: those with
self reported diagnosed diabetes, those without diagnosed
diabetes but had HbA1c ≥7% and the three tertiles of the
population with HbA1c<7%. Individuals without diag-
nosed diabetes but who had HbA1c ≥7% had higher mor-
tality than all others. Table 2 shows age and sex adjusted
mortality hazard ratios for these groups. Respondents
whose HbA1c was greater or equal to 7% but had not pre-
viously been diagnosed with diabetes had twice the rate of
death from all causes and dying from cardiovascular dis-
ease compared with respondents whose HbA1c was in the
lowest tertile. Respondents who reported diabetes also
had nearly double the death rate from cardiovascular dis-
ease compared with respondents whose HbA1c was in the
lowest tertile. The relative risks of ischaemic heart disease
and cerebro vascular disease mortality were higher in the
respondents who reported diabetes or whose HbA1c was
greater or equal to 7% but had no self-reported diabetes
than the lowest HbA1c tertile, although they are not signif-
icant at 5% level. There was no significant difference
between the three groups in which respondents' HbA1c
was less than 7%, although there may be a slight trend
with increasing tertiles. Adjusting for smoking status did
not change the patterns in the mortality hazard ratios.
Table 1: Characteristics of study population by HbA1c level and self reported diabetes. Values are number (%) in the category unless 
stated otherwise
Characteristic HbA1c (%) Self reported diabetes
3.7–5.2 5.3–5.7 5.8–6.9 ≥7T o t a l
Number (%) 372 (33) 345 (30) 287 (25) 36 (3) 99 (9) 1139
Age Median (IQR) 78 (73–84) 78 (74–85) 80 (75–86) 83 (77–89) 80 (75–86)
MMSE Median (IQR) 26 (22–28) 25 (23–28) 25 (21–28) 23 (20–25) 25 (22–28)
Sex Male 154 (41) 139 (40) 125 (43) 20 (56) 49 (49) 487
Social Class I/II 106 (28) 103 (30) 60 (21) 12 (33) 27 (27) 308
III 182 (49) 155 (45) 154 (54) 14 (39) 45 (46) 550
IV/V 73 (20) 77 (22) 64 (22) 10 (28) 23 (23) 247
Missing 11 (3) 10 (3) 9 (3) 0 (0) 4 (4) 34
Education <10 years 243 (65) 249 (72) 208 (72) 24 (67) 68 (69) 792
Smoking status Current smoker 46 (13) 49 (14) 68 (24) 6 (17) 20 (20) 189
Ex-smoker 197 (53) 154 (44) 128 (44) 18 (50) 44 (45) 541
Non smoker 124 (33) 140 (41) 90 (31) 12 (33) 28 (28) 336
M i s s i n g 5  ( 1 )2  ( 1 )1  ( 1 )0  ( 0 ) 3  ( 3 ) 1 1
ADL No impairment 206 (55) 177 (51) 138 (48) 11 (31) 34 (34) 566
IADL impairment 61 (17) 62 (18) 55 (19) 9 (25) 19 (19) 206
IADL and/or ADL impairment 93 (25) 93 (27) 78 (27) 16 (44) 41 (42) 321
Missing 12 (3) 13 (4) 16 (6) 0 (0) 5 (5) 46
History of Heart Attack 45 (12) 44 (13) 40 (14) 3 (8) 20 (21) 152
History of Stroke 36 (10) 42 (12) 36 (13) 4 (11) 21 (21) 139
History of High Blood Pressure 126 (34) 142 (41) 116 (40) 18 (50) 42 (42) 444BMC Public Health 2008, 8:54 http://www.biomedcentral.com/1471-2458/8/54
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Table 3 shows the relations between HbA1c level and/or
diabetes status and mortality from all cause, cardiovascu-
lar, ischaemic, cerebro vascular and non-cardiovascular
disease modeled using Cox multivariable regression mod-
els adjusted for age and sex only and additionally for his-
tory of heart attack, stroke, hypertension and smoking
status respectively. There is a continuous relationship
between HbA1c and mortality on all cause, cardiovascular
and ischaemic heart disease after taking of account of age,
sex and some known risk factors even including diabetes
status. An increase of 1% in HbA1c was associated with
about 10% (95% CI: 1% to 24%) increase in all cause
mortality and 20% increase in cardiovascular (95% CI:
7% to 37%) or ischaemic disease (95% CI: 4% to 44%)
mortality. However there was no significant association
between self reported diabetes status and mortality. The
risk associated with HbA1c is independent of self-
reported diabetes. After excluding the respondents with
self-reported diabetes or with a HbA1c level ≥ 7%, the rel-
ative risks of all cause, cardiovascular and ischaemic heart
disease were similar, but were no longer significant.
There were 99 people with self reported diagnosed diabe-
tes and of these one third had HbA1c concentration levels
below 7%. To examine whether this group of respondents
differed with respect to mortality from respondents who
reported diabetes but had HbA1c  concentration levels
above 7%, we separated the respondents into four groups:
• HbA1c < 7% without self reported diagnosis of diabetes
• HbA1c ≥ 7% and no self reported diabetes
All-cause mortality by five categories of respondents Figure 2
All-cause mortality by five categories of respondents.BMC Public Health 2008, 8:54 http://www.biomedcentral.com/1471-2458/8/54
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• reported diagnosed diabetes and HbA1c < 7%
• reported diagnosed diabetes and HbA1c ≥ 7%
Table 4 shows that respondents who had HbA1c ≥ 7% in
self reported diabetes group had significant higher hazard
rate of dying from cardiovascular disease and ischaemic
heart disease compared with the group of respondents
who had HbA1c < 7% and without self reported diagnosis
of diabetes even after adjusting for age and sex. Individu-
als who reported diabetes but were well controlled accord-
ing to HbA1c level had similar rates of death compared
with individuals who do not have diabetes, although the
confidence intervals are wide.
Table 2: Age and sex adjusted hazard ratios
Cause of death HbA1c (%) Self reported
T1 (3.7–5.2) T2 (5.3–5.7) T3 (5.8–6.9) ≥7 Diabetes
(n = 372) (n = 345) (n = 287) (n = 36) (n = 99)
All causes (n = 619) 176 177 170 27 69
Hazard ratio (95% CI) 1.0 1.1 (0.8,1.5) 1.3 (0.9,1.8) 2.0 (1.1,3.9) 1.4 (0.8 2.3)
Cardiovascular disease (n = 316) 86 86 88 15 41
Hazard ratio (95% CI) 1.0 1.1 (0.7,1.8) 1.4 (0.9,2.2) 2.1 (1.0,4.4) 1.9 (1.0,3.5)
Ischaemic heart disease (n = 165) 44 45 47 6 23
Hazard ratio (95% CI) 1.0 1.2 (0.7,2.1) 1.4 (0.8 2.5) 1.6 (0.5,5.5) 1.8 (0.8,4.0)
Cerebro vascular disease (n = 120) 34 37 26 6 17
Hazard ratio (95% CI) 1.0 1.1 (0.5,2.2) 1.1 (0.5,2.3) 2.5 (0.8,8.0) 1.7 (0.7,4.2)
Non-cardiovascular disease (n = 303) 90 91 82 12 28
Hazard ratio (95% CI) 1.0 1.1 (0.7,1.7) 1.1 (0.7,1.8) 1.8 (0.7,5.1) 1.0 (0.5,2.0)
Table 3: Cox multivariate regression for all cause, cardiovascular, ischaemic heart disease, cerebro disease and non-cardiovascular 
mortality. Effect of HbA1c level and diabetes status were modelled separately (models 1 and 2) and together (model 3)
Cause of death Relative risk adjusted for age & sex 
(95% CI)
P value Relative risk adjusted for age, sex and 
other risk factors* (95% CI)
P value
All causes (n = 619)
Model 1 HbA1c (per 1% increase) 1.1 (1.0,1.3) 0.03 1.1 (1.0, 1.2) 0.03
Model 2 Diabetes history (yes v no) 1.2 (0.8, 1.8) 0.38 1.2 (0.8, 1.9) 0.44
Model 3 HbA1c (per 1% increase) 1.2 (1.0, 1.3) 0.04 1.2 (1.0, 1.4) 0.08
Diabetes history (yes v no) 0.9 (0.6, 1.4) 0.67 0.8 (0.4, 1.6) 0.61
Cardiovascular disease (n = 316)
Model 1 HbA1c (per 1% increase) 1.2 (1.1, 1.4) 0.001 1.2 (1.1 1.4) 0.002
Model 2 Diabetes history (yes v no) 1.6 (1.0, 2.6) 0.056 1.5 (0.1, 2.6) 0.10
Model 3 HbA1c (per 1% increase) 1.2 (1.1, 1.4) 0.01 1.2 (1.1, 1.5) 0.01
Diabetes history (yes v no) 1.1 (0.6, 1.8) 0.79 0.9 (0.5, 1.8) 0.81
Ischaemic heart disease (n = 165)
Model 1 HbA1c (per 1% increase) 1.2 (1.1, 1.5) 0.01 1.2 (1.0, 1.4) 0.01
Model 2 Diabetes history (yes v no) 1.7 (1.0, 3.1) 0.08 1.5 (0.8, 3.0) 0.24
Model 3 HbA1c (per 1% increase) 1.2 (1.0, 1.5) 0.06 1.3 (1.0, 1.6) 0.03
Diabetes history (yes v no) 1.2 (0.6, 2.1) 0.63 0.8 (0.4, 1.9) 0.68
Cerebro disease (n = 120)
Model 1 HbA1c (per 1% increase) 1.2 (1.0, 1.5) 0.08 1.1 (0.9, 1.5) 0.29
Model 2 Diabetes history (yes v no) 1.6 (0.8, 3.3) 0.17 1.4 (0.7, 2.7) 0.40
Model 3 HbA1c (per 1% increase) 1.2 (0.9, 1.5) 0.29 1.1 (0.8, 1.6) 0.42
Diabetes history (yes v no) 1.2 (0.6, 2.8) 0.61 1.0 (0.4, 2.4) 0.97
Non-cardiovascular disease (n = 303)
Model 1 HbA1c (per 1% increase) 1.0 (0.9, 1.2) 0.87 1.0 (0.8, 1.2) 0.97
Model 2 Diabetes history (yes v no) 0.8 (0.5, 1.6) 0.58 0.8 (0.4, 1.7) 0.65
Model 3 HbA1c (per 1% increase) 1.1 (0.9, 1.4) 0.57 1.1 (0.8, 1.4) 0.68
Diabetes history (yes v no) 0.8 (0.4, 1.6) 0.46 0.7 (0.2, 2.2) 0.58
* Risk factors are history of heart attack, stroke, high blood pressure and smoke statusBMC Public Health 2008, 8:54 http://www.biomedcentral.com/1471-2458/8/54
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HbA1c and dementia
In this sample, dementia increased with age and was more
common in women (9.5%) than men (2.6%). There was
no cross sectional association between HbA1c level and
prevalent dementia, adjusted for sex and age at baseline.
There were 67 incident cases of dementia identified in 453
individuals during an average 5 years follow up since
HbA1c measurement. Dementia in this sample increased
with age and more women developed dementia (14.6%)
than men (4.9%). Table 5 shows the percentage of
respondents developing dementia over the 5 years, in
HbA1c ≥ 7% category this percentage was considerably
higher than other groups. The percentages in the three
other HbA1c groups were similar. The percentage develop-
ing dementia in the self reported diabetes group was low.
The crude death rate by 5 years was 70% among people
with self reported diabetes compared to 52% in partici-
pants with HbA1c level < 7%.
A logistic regression model found that respondents in the
group HbA1c ≥ 7% who had not been diagnosed with dia-
betes had significant higher risk (odds ratio = 4.8, 95%
CI:1.1 to 21.6) of developing dementia than the respond-
ents with HbA1c < 7% even after adjusting for age and sex.
HbA1c and disability
Table 1 shows that respondents who were in both self
reported diabetes category and no self reported diabetes
but with HbA1c level ≥7% category were more likely to
have IADL and/or ADL impairment at the time blood was
collected, even after adjusting for age and sex. But there
was no relationship between IADL and/or ADL impair-
ment and levels of HbA1cunder 7%.
114 respondents with no IADL or ADL impairment at the
time of blood collection had developed one in the five fol-
low up years. Overall there was no relationship between
the incidence of IADL and/or ADL impairment and HbA1c
level or diabetes status. Women with HbA1c level ≥7% had
60 % higher risk than women with HbA1c level in the
lower tertiles after adjusting for age, but confidence inter-
vals are wide (95% CI: 0.3, 9.5).
Discussion
The aim of this study is to investigate the relationship
between HbA1clevels and mortality, cognitive function
and physical disability in the older population in England
and Wales. It was found that there was a continuous rela-
tionship between HbA1c level and mortality from all
cause, cardiovascular and ischaemic heart disease.
Respondents who did not report diabetes but had HbA1c
Table 4: Age and sex adjusted hazards ratios
Not self reported diabetes Self reported diabetes
HbA1c (%)<7 HbA1c (%)≥7 HbA1c (%)<7 HbA1c (%)≥7
Cause of death (n = 1004) (n = 36) (n = 36) (n = 63)
All causes (n = 619) 523 27 25 44
Hazard ratio (95% CI) 1.0 1.8 (0.9,3.3) 1.2 (0.4,3.2) 1.3 (0.8,2.1)
Cardiovascular disease (n = 316) 260 15 10 31
Hazard ratio (95% CI) 1.0 1.9 (0.9,3.7) 0.5 (0.2,1.6) 2.1(1.2,3.7)
Ischaemic heart disease (n = 165) 136 6 6 17
Hazard ratio (95% CI) 1.0 1.4 (0.4,4.6) 0.5 (0.1,1.7) 2.1 (1.0,4.3)
Cerebro disease (n = 120) 97 6 3 14
Hazard ratio (95% CI) 1.0 2.4 (0.8,7.1) 0.6 (0.1,2.5) 2.0 (0.8,4.6)
Non-cardiovascular disease (n = 303) 263 12 15 13
Hazard ratio (95% CI) 1.0 1.7 (0.7,4.5) 1.8 (0.6,5.4) 0.6 (0.2,1.4)
Table 5: Percentages of individuals developing dementia over 5 years follow-up within each HbA1c group
HbA1c (%) Self reported
T1 (3.7–5.2) T1 (5.3–5.7) T1 (5.8–6.9) ≥7a Diabetes
Total 372 345 287 36 99
Number of Casesb 62 63 43 14 10
Cumulative Incidenceb 10.7 10.9 11.8 49.1 7.5
95% CIb (5.3,20.4) (5.9,19.2) (6.1,21.7) (14.7,84.4) (1.9,16.8)
a Not self-reported diabetes
b Number of cases, incidence and CI are back-weighted to the population sampleBMC Public Health 2008, 8:54 http://www.biomedcentral.com/1471-2458/8/54
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≥7 % had the highest mortality rate from all causes and
cardiovascular disease independent of age and sex com-
pared with respondents in the lowest HbA1c tertile.
Respondents with a known history of diabetes were at an
increased risk of dying from cardiovascular disease inde-
pendent of age and sex. However respondents with
known history of diabetes, but with HbA1c under 7% had
similar rates of the mortality to respondents without dia-
betes whose HbA1c level were also under 7%. Individuals
with poorly controlled known diabetes had the highest
mortality risk.
In the main analysis of mortality, we adjusted only age
and sex. In order to see if confounding factors would
influence the results, we also performed sensitivity analy-
sis adjusted for all the available risk factors in our study
such as history of heart attack, stroke, high blood pressure
and smoke status, and there were no significant changes.
We would have liked to include some possible confound-
ing factors such as BMI, but unfortunately the information
was not collected in our study.
In contrast to established literature this analysis did not
show that individuals with diagnosed diabetes were at
higher risk of developing dementia [5]. There was no evi-
dence to suggest that HbA1c level was related to the current
dementia. However, there was a significant increase in the
risk of developing dementia for individuals with HbA1c ≥7
% but who did not report they had been previously diag-
nosed with diabetes. It may be that some of the people
who would have developed dementia had they survived
were differentially lost to follow up because of premature
mortality due to diabetes. Since overall prevalence of
dementia at death was 30% and there was a strong
increasing trend for dementia with age from 6% for those
aged 65–69 years old at time of death to 58% for those
aged 95 years old and above at time of death [22], there
might be more incident cases missed from this high mor-
tality group. In addition, the low incidence rate in this
group might well be by chance.
However, considering that the mortality in HbA1c ≥ 7%
but no self-reported diabetes category was high, these
biases would imply that the incidence rate of dementia
would be even higher than observed. Figure 2 shows that
a higher early mortality from all-cause, and particularly
from non-cardiovascular causes was seen in those with
HbA1c ≥ 7%, compared to the other groups (including
self-reported diabetes). These findings support the obser-
vation that at diagnosis of diabetes half already have clin-
ical evidence of diabetic tissue damage and that
cardiovascular risk factors are common [23,24]
The relative risks in our study were not as substantial as
those found elsewhere [7,8]. This may be due to the differ-
ences in the populations studied, and attrition of effects
with age. In the EPIC-Norfolk study, the respondents are
much younger (45–79 years) compared with CFAS where
the respondents were aged 69–103 years. There were con-
tinuous relationships between increasing HbA1c level and
the increasing risks of death from all cause, cardiovascular
and ischaemic heart disease after taking into account of
age, sex and some known risk factors even including dia-
betes status in the models, though no relationship was
found to subsequent non cardiovascular disease and cere-
brovascular disease deaths.
Individuals who had a HbA1c ≥ 7% were informed via
their GP of this fact, though we did not specifically follow
up on treatment or confirmation of the diagnosis within
these individuals. Information was requested about dia-
betes history at the next routine interview (four years
later). Some individuals will have been treated, therefore
it could be that we have under estimated the morbidity/
mortality of undiagnosed diabetes.
Increasing HbA1c level was not associated with risk of
developing IADL and/or ADL impairment in the whole
sample population, but it was associated with an increas-
ing risk of developing IADL and/or ADL impairment in
women. We also have found the evidence to support pre-
vious literature that community-living older subjects with
diabetes have high rates of deficits in physical function
[5], however, our results showed that the incidence rates
are similar in each category, this possibly due to a small
number of diabetic patients in our sample and older age
groups with increasing impairments in the whole popula-
tion.
Missing data at the longitudinal follow-ups are a potential
problem for all longitudinal studies. Excluding deaths,
25% of individuals with a HbA1c measurement did not
have a follow-up interview. This could be a problem for
estimation of incidence of dementia as this is associated
with dropout [25]. If this relationship did exist, it would
accentuate the differences between those with and with-
out cognitive decline as those with cognitive decline
would be missed. However this will only affect the esti-
mates if dropout is independently related to HbA1c levels
or diabetes. There is no evidence to suggest this [25].
Various HbA1c thresholds have been proposed for indicat-
ing blood sugar control. We have used 7% as this was the
recommended level at the time of the study. This will not
be consistent with other studies [26]. The classification of
diabetes will therefore be different to some reported find-
ings [27]. In addition, respondents were divided into
three groups using tertiles of HbA1c for those with HbA1c
under 7 %, which caused different cut points from some
studies such as the one used in EPIC-Norfolk. Using EPIC-BMC Public Health 2008, 8:54 http://www.biomedcentral.com/1471-2458/8/54
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Norfolk [7,8] cut points in the survival analysis may make
the results more easily comparable with this study, how-
ever these cut points were based on measurements of par-
ticipants with a very different age range (45–79 years).
Individuals who had self-reported diabetes but whose
HbA1c was under 7% had mortality and dementia inci-
dence comparable to individuals without diabetes and
HbA1c <7%. While these results suggest that treating dia-
betes reduces risk of mortality and dementia, other expla-
nations for our findings need to be considered.
The association between abnormal glucose regulation and
cardiovascular disease is well known. However, this may
not be a direct causal association. It is hypothesized that
the constellation of cardiovascular risk factors that consti-
tute the metabolic syndrome (elevated glucose, hyperten-
sion, dyslipidaemia and central obesity) share a common
causal factor. Insulin resistance is a typical feature of indi-
viduals with the metabolic syndrome [28]. HbA1c could
therefore be a risk marker for other cardiovascular risk fac-
tors.
Alternatively, there are mechanisms that may directly link
HbA1c  with dementia and cardiovascular disease.
Advanced glycated end products are formed when pro-
teins are exposed to glucose in a process analogous to for-
mation of HbA1c where glucose binds to haemoglobin.
They have been implicated in diabetic vascular disease
[29] and may be related to the development of Alzhe-
imer's Disease [30].
Conclusion
The findings from this study provide further evidence for
HbA1c as an indicator of future health. To control HbA1c
level effectively under 7% may reduce the risks of dying
from cardiovascular disease and ischaemic heart disease
and contribute to maintenance of cognitive function in
the older population.
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